scholarly journals Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center

2021 ◽  
Vol 13 (3) ◽  
pp. 116-120
Author(s):  
Murat Bektaş ◽  
Çiğdem Çetin ◽  
Çağrı Burak Uğurlu ◽  
Fatih Kemik ◽  
Ahmet Can Çiftçi ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Real Life ◽  
Single Center ◽  
Life Data ◽  
Real Life Data

Effects of Salazopyrin Used in Axial Spondyloarthritis on COVID-19 Outcomes: Real-Life Data from a Single Center

2021 ◽  
Author(s):  
Berkan Armağan ◽  
Ebru Atalar ◽  
Serdar Can Güven ◽  
Bahar Özdemir ◽  
Hatice Ecem Konak ◽  
...  
Keyword(s):  
Axial Spondyloarthritis ◽  
Real Life ◽  
Single Center ◽  
Life Data ◽  
Real Life Data

scholarly journals Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

RMD Open ◽  
2020 ◽  
Vol 6 (3) ◽  
pp. e001280
Author(s):  
Brigitte Michelsen ◽  
Ulf Lindström ◽  
Catalin Codreanu ◽  
Adrian Ciurea ◽  
Jakub Zavada ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Axial Spondyloarthritis ◽  
Real Life ◽  
Routine Care ◽  
Retention Rates ◽  
Inactive Disease ◽  
Life Data ◽  
Real Life Data ◽  
Time Since Diagnosis

ObjectivesTo explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.MethodsReal-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)).ResultsWe included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70–93%, 12-month: 53–86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness.ConclusionsIn this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.

scholarly journals Real Life Data for Glecaprevir/Pibrentasvir: A Single-Center Study

2021 ◽  
Vol 2 (1) ◽  
pp. 14-18
Author(s):  
Fatma Çölkesen ◽  
Arzu Tarakçı ◽  
Fatma Kaçar ◽  
Esma Eroğlu ◽  
Şule Özdemir Armağan
Keyword(s):  
Real Life ◽  
Single Center ◽  
Life Data ◽  
Real Life Data ◽  
Single Center Study ◽  
Center Study

scholarly journals Advantages of Tailored Isotretinoin Treatment in Moderate to Severe Acne: Real-Life Data

2021 ◽  
Vol 12 ◽  
Author(s):  
Nevena Skroza ◽  
Ersilia Tolino ◽  
Veronica Balduzzi ◽  
Nicoletta Bernardini ◽  
Alessandra Mambrin ◽  
...  
Keyword(s):  
Dose Adjustment ◽  
Systemic Treatment ◽  
Real Life ◽  
Efficacy And Safety ◽  
Single Center ◽  
Severe Acne ◽  
Life Data ◽  
Real Life Data ◽  
Single Center Study ◽  
Center Study

This retrospective single-center study analyzes the efficacy and safety of isotretinoin for the treatment of moderate to severe acne in real-life clinical practice, particularly with regard to acne severity, isotretinoin cumulative dosage, and patients’ gender. The results suggest the opportunity of an early isotretinoin systemic treatment in patients affected by moderate acne and emphasize the importance of an appropriate dose adjustment in order to minimize adverse events.

Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data

2019 ◽  
Vol 111 (3) ◽  
pp. 262-269 ◽  
Author(s):  
Döndü Üsküdar Cansu ◽  
Hava Üsküdar Teke ◽  
Tuncer Temel ◽  
Adem Ertürk ◽  
Osman Kahraman ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Ankylosing Spondylitis ◽  
Bowel Disease ◽  
Real Life ◽  
Disease Evolution ◽  
Life Data ◽  
Real Life Data ◽  
Inflammatory Bowel

scholarly journals Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction

RMD Open ◽  
2016 ◽  
Vol 2 (2) ◽  
pp. e000272 ◽  
Author(s):  
X Baraliakos ◽  
F Heldmann ◽  
F van den Bosch ◽  
G Burmester ◽  
H Gaston ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Dose Reduction ◽  
Real Life ◽  
Life Data ◽  
Real Life Data
Sign in / Sign up

Export Citation Format

Share Document